Pharmacokinetics and efficacy of intrathecal VersaMab-101 delivery foracute spinal cord injury
鞘内 VersaMab-101 递送治疗急性脊髓损伤的药代动力学和疗效
基本信息
- 批准号:10484664
- 负责人:
- 金额:$ 49.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdultAgreementAnimal ModelAntibodiesAntibody TherapyAxonBehaviorBiodistributionBiological AssayBiological Response Modifier TherapyBloodBlood - brain barrier anatomyBolus InfusionBrainBusinessesCaliforniaChestClinicClinicalClinical TreatmentClinical TrialsCommunitiesCommunity DevelopmentsContinuous InfusionContusionsCuesDataData SetDevelopmentDevelopment PlansDevicesDiagnosisDoseDrug KineticsEmbryoEngineeringEnzyme-Linked Immunosorbent AssayFDA approvedFormulationFundingFutureGoalsHeartHistologicHospitalsHumanImmunohistochemistryIn VitroIndividualInfusion proceduresInjuryKidneyLaboratoriesLegal patentLesionLicensingLiquid substanceLiverLiving CostsLocomotionLungMeasuresMechanicsMedicalModelingMolecularMonoclonal AntibodiesMonoclonal Antibody TherapyMusNational Institute of Neurological Disorders and StrokeNeuraxisOutcomePatientsPermeabilityPersonsPharmaceutical PreparationsProteinsPublishingPumpQuadriplegiaRattusRecoveryRecovery of FunctionRegimenRodent ModelSafetySamplingSeriesSerumSiteSmall Business Innovation Research GrantSolidSpinal CordSpinal cord injurySpinal cord injury patientsSystemTestingTimeTissuesToxic effectUnited StatesUniversitiesWalkingWorkallodyniaaxon guidanceaxon injurybasechronic painclinical developmentdrug developmentexperiencefunctional improvementhumanized antibodyimmunogenicityimprovedimproved outcomein vivolead candidatelife time costmotor controlneurological recoverynovelnovel therapeuticspotency testingprofessorprogramsreceptorregenerative growth
项目摘要
PROJECT SUMMARY/ABSTRACT
Every year in the United States, approximately 17,800 people suffer acute spinal cord injuries (SCI).
While recent advances in the medical management of SCI have led to improvements in the diagnosis and
stabilization of these patients, there has been minimal progress made towards improving outcomes with current
treatment options. For instance, fewer than 1% of individuals experience complete neurological recovery by the
time of hospital discharge, and the lifetime costs of living with an SCI can average up to $5.1M for individuals
with high tetraplegia. VersaPeutics is a small business that is developing VersaMab-101, a novel monoclonal
antibody therapy for acute SCI. Traditionally, biologic therapeutics for SCI have been delivered intrathecally via
osmatic pump into the spinal cord. Our previously study has demonstrated the stability of VersaMab-101 in one
of the FDA approved programmable pump under a simulated clinic administration. In the present study, we will
examine the pharmacokinetics and efficacy of intrathecally administration of VersaMab-101 by using rodent
models of SCI. At the end of this project, we expect to have high quality datasets that will inform our clinical
development plans for VersaMab-101 and also will be published to help the spinal cord injury drug development
community.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Miao Sun其他文献
Miao Sun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Miao Sun', 18)}}的其他基金
Toxicology and Efficacy Studies of Intrathecal VersaMab-101 for spinal cord injury treatment
鞘内注射 VersaMab-101 治疗脊髓损伤的毒理学和疗效研究
- 批准号:
10697262 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Developing therapeutic antibodies for Alzheimer's disease
开发阿尔茨海默病的治疗抗体
- 批准号:
10821560 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Developing therapeutic antibodies for Alzheimer's disease
开发阿尔茨海默病的治疗抗体
- 批准号:
10484675 - 财政年份:2022
- 资助金额:
$ 49.51万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)